BlackRock
REGN icon

BlackRock’s Regeneron Pharmaceuticals REGN Stock Holding History

BlackRock’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000
Closed -$525K – 5576
2025
Q2 		$525K Buy
+1,000
New +$558K ﹤0.01% 4429

Other funds holding REGN

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

BlackRock's REGN Position: Q2 2026 in Review

BlackRock increased its Regeneron Pharmaceuticals (REGN) stake by 1.9% in Q2 2026, buying an estimated $113M and bringing the position to 9,113,506 shares worth $5.68B. The position accounts for 0.08% of the portfolio, ranked #196.

BlackRock first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.91B in Q3 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • BlackRock held 9,113,506 shares of Regeneron Pharmaceuticals worth $5.68B as of Q2 2026.
  • BlackRock bought 165,771 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $113M.
  • Regeneron Pharmaceuticals made up 0.08% of BlackRock's portfolio in Q2 2026, its #196 holding.
  • BlackRock first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • BlackRock's Regeneron Pharmaceuticals position peaked at $8.91B in Q3 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.